Cargando…
MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
The cancer drug gemcitabine (GEM) is a key drug for treating pancreatic ductal adenocarcinoma (PDAC), but PDAC cells develop chemoresistance after long-term administration. Since the tolerance was immediately spread to every PDAC tissue in a patient, it is assumed that some certain efficient mechani...
Autores principales: | Mikamori, Manabu, Yamada, Daisaku, Eguchi, Hidetoshi, Hasegawa, Shinichiro, Kishimoto, Tomoya, Tomimaru, Yoshito, Asaoka, Tadafumi, Noda, Takehiro, Wada, Hiroshi, Kawamoto, Koichi, Gotoh, Kunihito, Takeda, Yutaka, Tanemura, Masahiro, Mori, Masaki, Doki, Yuichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5309735/ https://www.ncbi.nlm.nih.gov/pubmed/28198398 http://dx.doi.org/10.1038/srep42339 |
Ejemplares similares
-
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
por: Nishi, Hidemi, et al.
Publicado: (2023) -
Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer
por: Shinke, Go, et al.
Publicado: (2018) -
MicroRNA‐181b‐5p, ETS1, and the c‐Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy
por: Tomihara, Hideo, et al.
Publicado: (2017) -
Tumor endothelial cell‐induced CD8(+) T‐cell exhaustion via GPNMB in hepatocellular carcinoma
por: Sakano, Yoshihiro, et al.
Publicado: (2022) -
Prognostic value of functional SMAD4 localization in extrahepatic bile duct cancer
por: Takayama, Hirotoshi, et al.
Publicado: (2022)